Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective
Pharmaceuticals · 2026-07-24 · 19 (8) · 1146
DOI: 10.3390/ph19081146 ↗At a glance
Übersichtsarbeit in Pharmaceuticals, published online on 2026-07-24. Written by Nicolò Bisi and 1 co-authors. Institution: Department of Chemistry, Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17, Av. des Sciences, 91400 Orsay, France. Cited 1 times so far (Crossref); 113 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background/Objectives: Cancer resistance, pathway redundancy, and compensatory signaling challenge traditional therapies. Dual target strategies address this by engaging two disease-relevant proteins within a single molecule. This review compares classical dual inhibitors with dual proteolysis-targeting chimeras (dual PROTACs) to evaluate the therapeutic advantages of degradation over occupancy.
Methods
We examine oncology target pairs featuring documented examples of both dual inhibitors and dual PROTACs. The biological rationale for co-targeting is analyzed alongside a comparative assessment of their chemical frameworks, focusing heavily on the synthetic strategies, length, and structure of linkers required for dual PROTAC ternary complex formation.
Results
While dual inhibitors rely on active-site occupancy, dual PROTACs leverage the ubiquitin–proteasome system for catalytic target elimination. Transitioning from dual inhibition to dual degradation in most cases (>85%) enhances antitumor efficacy, extends duration of action, and overcomes resistance mutations. Optimizing linker design remains the critical factor in balancing the simultaneous degradation kinetics of two distinct proteins.
Conclusions
Dual PROTACs provide distinct advantages over traditional inhibitors by completely destroying target proteins rather than merely blocking them. This comparison offers a practical entry point and actionable synthetic strategies for medicinal chemists designing multi-target protein degraders.
Subjects
Author keywords
Authors and institutions
- Department of Chemistry, Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17, Av. des Sciences, 91400 Orsay, France.
ORCID profiles: Nicolò Bisi, Abdallah Hamze
Cite
APA
Bisi, N., & Hamze, A. (2026). Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. Pharmaceuticals, 19(8), 1146. https://doi.org/10.3390/ph19081146
Vancouver
Bisi N, Hamze A. Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. Pharmaceuticals. 2026;19(8):1146. doi:10.3390/ph19081146
BibTeX
@article{Bisi2026,
author = {Bisi, Nicolò and Hamze, Abdallah},
title = {Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1146},
doi = {10.3390/ph19081146}
}
EUVIMED